(19)
(11) EP 1 405 912 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.10.2012 Bulletin 2012/43

(45) Mention of the grant of the patent:
05.09.2012 Bulletin 2012/36

(21) Application number: 02745822.3

(22) Date of filing: 04.07.2002
(51) International Patent Classification (IPC): 
C12P 21/02(2006.01)
(86) International application number:
PCT/JP2002/006770
(87) International publication number:
WO 2003/004647 (16.01.2003 Gazette 2003/03)

(54)

GENETICALLY MODIFIED ECARIN AND PROCESS FOR PRODUCING THE SAME

GENETISCH MODIFIZIERTES ECARIN UND VERFAHREN ZU DESSEN HERSTELLUNG

ECARINE GENETIQUEMENT MODIFIEE ET PROCEDE D'ELABORATION

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

(30) Priority: 06.07.2001 JP 2001206918

(43) Date of publication of application:
07.04.2004 Bulletin 2004/15

(73) Proprietor: The Chemo-Sero-Therapeutic Research Institute
Kumamoto-shi Kumamoto 860-8568 (JP)

(72) Inventors:
  • YONEMURA, Hiroshi
    Kikuchi-gun, Kumamoto 869-1298 (JP)
  • IMAMURA, Takayuki
    Kikuchi-gun, Kumamoto 869-1298 (JP)
  • NAKATAKE, Hiroshi
    Kikuchi-gun, Kumamoto 869-1298 (JP)
  • SOEJIMA, Kenji
    Kikuchi-gun, Kumamoto 869-1298 (JP)
  • NOZAKI, Chikateru
    Kikuchi-gun, Kumamoto 869-1298 (JP)

(74) Representative: Vossius & Partner 
Siebertstrasse 4
81675 München
81675 München (DE)


(56) References cited: : 
WO-A-01/04146
 US-A- 5 602 034
   
  • HOFMANN H ET AL: "BLOOD COAGULATION INDUCED BY THE VENOM OF BOTHROPS ATROX. I. IDENTIFICATION, PURIFICATION AND PROPERTIES OF A PROTHROMBIN ACTIVATOR" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 26, no. 3, 1987, pages 772-780, XP001063236 ISSN: 0006-2960
  • NOMURA M ET AL: "In vivo induction of cytotoxic T lymphocytes specific for a single epitope introduced into an unrelated molecule" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 193, no. 1, 14 June 1996 (1996-06-14), pages 41-49, XP004020801 ISSN: 0022-1759
  • RAKONJAC J ET AL: "Filamentous phage are released from the bacterial membrane by a two-step mechanism involving a short C-terminal fragment of pIII" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 289, no. 5, 25 June 1999 (1999-06-25), pages 1253-1265, XP004451670 ISSN: 0022-2836
  • NISHIDA S. ET AL.: 'cDNA cloning and deduced amino acid sequence of prothrombin activator (ecarin) from Kenyan Echis carinatus venom' BIOCHEMISTRY vol. 34, no. 5, 1995, pages 1771 - 1778, XP002159171
  • MORITA T. ET AL.: 'Purification and properties of prothrombin activator from the venom of Echis carinatus' J. BIOCHEM. vol. 83, no. 2, 1978, pages 559 - 570, XP002955637
  • BRIET E. ET AL.: 'Cleavage and activation of human prothrombin by Echis carinatus venom' THROMB. RES. vol. 27, no. 5, 1982, pages 591 - 600, XP002955638
  • YAMAMOTO ET AL: JOURNAL OF CHROMATOGRAPHY, vol. 852, 1999, pages 37-41, XP004176667,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).